An attorney involved in the first anti-inflammatory class actions predicts Vioxx litigation could dwarf every other product liability mass tort other than asbestos and tobacco.

One day after Merck & Co. announced the recall of its anti-inflammatory drug Vioxx, a prominent Long Island plaintiffs lawyer filed two product liability lawsuits against the drug company in the Nassau County Supreme Court.

Robert G. Sullivan, senior partner in the Mineola, N.Y., office of Sullivan Papain Block McGrath & Cannavo, said the suits are the first in New York to his knowledge.

More suits are already in the works, he said. By late last week, Sullivan’s firm had already signed up more than 200 Vioxx clients, he said.

Six Sullivan Papain attorneys have been assigned to handle case intake, five in the firm’s Long Island office, the sixth in Manhattan. The firm has a third office in Hackensack, N.J. They are “receiving calls all day long,” he added.

Helped, at least in part, by a full page ad in the Oct. 6 edition of New York Newsday, Sullivan said, his firm is getting 50 to 60 new cases daily.

Sullivan predicts that given the number of people taking the drug, within the next four years national Vioxx litigation could come to dwarf every other product liability mass tort except for asbestos and tobacco. Sullivan is intent on having his firm lead the way.

Merck & Co. spokespeople declined to talk about how the company will handle the rising tide of litigation. Theodore V.H. Mayer of Hughes Hubbard & Reed, one of the pharmaceutical company’s outside counsel, said that Merck’s lawyers are reliant upon the defenses of full disclosure and lack of causation.

Veteran products liability defense attorney William M. Savino, who is not connected with the case or either side, cautioned, “It’s one thing to try your case on the six o’clock news. It’s another thing to put your proofs to the jury.” Savino is managing partner at Rivkin Radler.

A POPULAR PRESCRIPTION

Approved by the federal Food and Drug Administration in 1999, and brought to the market that year, Vioxx was one of a class of non-steroidal anti-inflammatory drugs called “Cox-2 inhibitors,” named after the enzyme they block. Other name-brand drugs in the same class are Celebrex and Bextra, both made by Pfizer.

All three became popular as arthritis pain relievers. It is that popularity that Sullivan is banking on. “There were 80 million people on this drug,” he said.

That figure is contested by Merck. Spokesman Antonius Plohoros said that while 100 million prescriptions have been written for the drug, it had only 20 million users in the United States.

Merck announced its voluntary recall of the drug on Sept. 21, four days after receiving a warning letter from the FDA. That letter chastised the company for engaging in a promotional campaign for Vioxx “that minimizes the potentially serious cardiovascular findings” revealed during the company’s study of the drug’s gastrointestinal effects.

Sullivan asserted that a Vioxx user was 50 percent more likely to suffer a heart attack than users of the other Cox-2 drugs.

According to the pleadings, each of the plaintiffs in the suits filed by Sullivan suffered heart attacks. Echoing the FDA letter, each of those filed complaints accuses the company of minimizing the risk of cardiovascular injury. Both allege a breach of duty to disclose that risk; that the pills weren’t safe for their intended use; and that the company’s advertising was misleading.

In accordance with New York State law, neither complaint makes an express demand for a particular sum of money. Both, however, request a sum “in excess of the jurisdictional limits” of the court.

The results of the gastrointestinal study were reported to the FDA and published in the New England Journal of Medicine. The information available from placebo-controlled clinical trials at the time supported the cardiovascular safety of the drug and the doctors made the ultimate decision to prescribe the medication based upon available clinical trials and their knowledge of their own patients, Mayer said.

Scroll to Top